Get the Stockscreener App
1.20
0.83%
-0.01
After Hours:
1.21
0.01
+0.83%
Milestone Pharmaceuticals Inc stock is traded at $1.20, with a volume of 1.58M.
It is down -0.83% in the last 24 hours and up +2.56% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
See More
Previous Close:
$1.21
Open:
$1.21
24h Volume:
1.58M
Relative Volume:
1.12
Market Cap:
$149.40M
Revenue:
$1.78M
Net Income/Loss:
$-68.36M
P/E Ratio:
-1.7575
EPS:
-0.6828
Net Cash Flow:
$-51.59M
1W Performance:
+3.45%
1M Performance:
+2.56%
6M Performance:
-27.27%
1Y Performance:
-32.58%
1-Day Range:
$1.195
$1.26
1-Week Range:
$1.115
$1.26
52-Week Range:
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.20 | 128.23M | 1.78M | -68.36M | -51.59M | -0.6828 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Upgrade | TD Cowen | Hold → Buy |
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone Pharma's nasal spray gets first ex-US approval - The Pharma Letter
Milestone Pharmaceuticals Inc. (MIST) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
MIST Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Milestone Pharmaceuticals (MIST) Gains China Approval for Etripa - GuruFocus
Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co - TradingView
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States - Yahoo Finance
Milestone Pharmaceuticals Inc. (MIST) Key Financial Ratios – Valuation, Profitability & More - Value Research
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences - The Manila Times
Three investor events are set for Boston and New York, with Milestone joining - Stock Titan
Milestone Pharmaceuticals stock holds at $1.16 as fundamentals and outlook stay in focus - AD HOC NEWS
Milestone Pharmaceuticals Inc. (MIST) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Milestone presents study on PSVT impact between episodes By Investing.com - Investing.com Canada
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes - globenewswire.com
Milestone presents study on PSVT impact between episodes - Investing.com
First Patient Enrolled in the Phase 3 ReVeRA-301 Pivotal Trial for Afib - dicardiology.com
Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation - Yahoo
Milestone (MIST) Results Breakdown: EPS Comes in Below Forecast in Latest Trading; Latest Reaction: The Stock Records a 2.43% Increase for the Current SessionFree Cash Flow Trends - vinanet.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Advances Trial Path - Kalkine Media
Milestone Pharmaceuticals begins phase 3 trial for AFib treatment By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial - Yahoo Finance
Milestone Pharmaceuticals (MIST) Launches Phase 3 Trial Amidst High Price-to-Sales Valuation - GuruFocus
Milestone Pharmaceuticals stock gains on Phase 3 AFib trial By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals stock gains on Phase 3 AFib trial - Investing.com
Milestone Pharmaceuticals begins phase 3 trial for AFib treatment - Investing.com
Milestone Pharmaceuticals Enrolls First Patient in Phase 3 ReVeRA-301 Trial of Etripamil for AFib-RVR - Quiver Quantitative
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) - The Manila Times
This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Cantor Fitzgerald initiates Milestone Pharmaceuticals stock coverage with overweight rating - Investing.com Canada
MIST Initiated Coverage by Cantor Fitzgerald -- Rating Overweight - GuruFocus
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound (NASDAQ:MIST) - Seeking Alpha
Milestone Pharmaceuticals (MIST) Climbs 2.8% as Shares Hold Above $1.04 SupportShort Setup Alerts - vinanet.vn
Milestone’s FDA Win Now Faces A Tougher Test: Sales - Finimize
What is HC Wainwright's Forecast for MIST Q3 Earnings? - MarketBeat
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Earnings To Watch: Milestone Scientific Inc (MLSS) Q2 2026 -- GF Value Sees 13% Upside - finance.yahoo.com
What is HC Wainwright's Estimate for MIST FY2028 Earnings? - MarketBeat
Wells Fargo Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Milestone Pharmaceuticals earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Milestone Pharmaceuticals Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Milestone Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Milestone Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Milestone Pharmaceuticals Q2 Results: Net loss widens to $28.6M - scanx.trade
Milestone Pharmaceuticals Inc (MIST) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Milestone posts Q2 loss as CARDAMYST launch gains traction - Investing.com
Q2 2026 Milestone Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Form 8K MILESTONE PHARMACEUTICALS INC. For: 12 August By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Milestone Pharmaceuticals shares tumble after Q2 earnings miss - Yahoo Finance
Milestone Pharmaceuticals stock tumbles 12% on Q2 earnings miss By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):